Inhibikase Therapeutics Inc. (IKT)
NASDAQ · Healthcare
Inhibikase Therapeutics Inc. Cash on Hand 2020–2024
Inhibikase Therapeutics Inc. annual cash on hand history from 2021 to 2024. Cash on hand refers to the total amount of cash and cash equivalents held by a company.
- Inhibikase Therapeutics Inc. cash on hand as of December 31, 2024: 97.5M, a 959.78% increase year-over-year.
- Inhibikase Therapeutics Inc. cash on hand for 2024 were 97.5M, a 959.78% increase from 2023.
- Inhibikase Therapeutics Inc. cash on hand for 2023 were 9.2M, a 27.96% increase from 2022.
- Inhibikase Therapeutics Inc. cash on hand for 2022 were 7.2M, a 82.36% decrease from 2021.
- Inhibikase Therapeutics Inc. cash on hand for 2021 were 40.8M.
Cash on Hand
ANNUAL · $B
YEAR-OVER-YEAR GROWTH · %
| Inhibikase Therapeutics Inc. Annual Cash on Hand (Millions of US $) | |
|---|---|
| 2024 | $98 |
| 2023 | $9 |
| 2022 | $7 |
| 2021 | $41 |
Inhibikase Therapeutics Inc. Cash on Hand — FAQ
Inhibikase Therapeutics Inc. (IKT) cash on hand over the last 5 years — annual and quarterly figures with year-over-year growth and charts.
Where can I see IKT's cash on hand history?
The chart and table above show Inhibikase Therapeutics Inc.'s cash on hand by year and by quarter, including the growth rate.